ACTR-IIA Inhibitors
The chemical class of Activin Receptor Type-2A inhibitors primarily comprises molecules that target related kinases and signaling pathways, given the limited availability of direct inhibitors for ACTR-IIA. These inhibitors focus on modulating the TGF-β/Activin/Nodal and BMP (Bone Morphogenetic Protein) pathways, which are crucial for the functional regulation of ACTR-IIA. TGF-β pathway inhibitors like SB-431542, LY2109761, A-83-01, RepSox, GW788388, and Vactosertib selectively inhibit type I receptors (ALK4, ALK5, ALK7), crucial for the downstream signaling of TGF-β. This inhibition leads to the modulation of cellular processes such as proliferation, differentiation, and apoptosis, indirectly affecting ACTR-IIA functions.
In contrast, chemicals like LDN-193189, DMH1, Dorsoomorphin, K02288, LDN-214117, and LDN-212854 target the BMP pathway by selectively inhibiting ALK2, ALK3, and ALK6. The BMP signaling pathway intersects with the functional domain of ACTR-IIA, especially in the context of cellular growth and differentiation. By inhibiting these kinases, these chemicals can modulate the activity of ACTR-IIA indirectly. It's important to note that these inhibitors are used primarily for research purposes to understand the complex interactions within TGF-β and BMP signaling pathways and their impact on ACTR-IIA functions.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $82.00 $216.00 $416.00 | 48 | |
SB-431542 is a potent and selective inhibitor of ALK5 (TGF-β type I receptor), which indirectly affects ACTR-IIA signaling by blocking the TGF-β pathway. | ||||||
4-(6-(4-(Piperazin-1-yl)phenyl)pyrazolo[1,5-a]pyrimidin-3-yl)quinoline | 1062368-24-4 | sc-476297 | 5 mg | $240.00 | ||
LDN-193189 is a selective inhibitor of ALK2 and ALK3, which are closely related to ACTR-IIA, thus potentially modulating its signaling pathway. | ||||||
DMH-1 | 1206711-16-1 | sc-361171 sc-361171B sc-361171A sc-361171C | 10 mg 25 mg 50 mg 100 mg | $213.00 $318.00 $632.00 $1047.00 | 2 | |
DMH1 selectively inhibits ALK2, a protein kinase related to ACTR-IIA, impacting the BMP signaling pathway that intersects with ACTR-IIA functions. | ||||||
A 83-01 | 909910-43-6 | sc-203791 sc-203791A | 10 mg 50 mg | $202.00 $811.00 | 16 | |
A-83-01 is a potent inhibitor of ALK5, ALK4, and ALK7, affecting the TGF-β/Activin/Nodal signaling and indirectly influencing ACTR-IIA activity. | ||||||
LY2109761 | 700874-71-1 | sc-396262 sc-396262A | 1 mg 5 mg | $89.00 $275.00 | 9 | |
LY2109761 inhibits TGF-β receptors ALK5 and ALK4, indirectly affecting ACTR-IIA signaling involved in fibrosis and cancer pathways. | ||||||
BML-275 | 866405-64-3 | sc-200689 sc-200689A | 5 mg 25 mg | $96.00 $355.00 | 69 | |
Dorsoomorphin targets ALK2, ALK3, and ALK6, which are part of the BMP signaling pathway and indirectly influence ACTR-IIA signaling. | ||||||
K02288 | 1431985-92-0 | sc-488981 | 5 mg | $330.00 | ||
K02288 is a selective ALK2 inhibitor, potentially modifying the BMP pathway and thereby affecting ACTR-IIA signaling indirectly. | ||||||
ALK5 Inhibitor II | 446859-33-2 | sc-221234 sc-221234A sc-221234B sc-221234C sc-221234D sc-221234E sc-221234F | 1 mg 5 mg 10 mg 50 mg 100 mg 500 mg 1 g | $77.00 $153.00 $219.00 $663.00 $1248.00 $4382.00 $7850.00 | 8 | |
RepSox, also known as SJN 2511, inhibits ALK5 and thereby indirectly modulates ACTR-IIA signaling through the TGF-β pathway. | ||||||
LDN-214117 | 1627503-67-6 | sc-507451 | 5 mg | $165.00 | ||
LDN-214117 is a potent and selective ALK2 inhibitor, potentially affecting ACTR-IIA signaling by altering BMP pathway dynamics. | ||||||
GW788388 | 452342-67-5 | sc-363544 sc-363544A | 5 mg 25 mg | $95.00 $384.00 | ||
GW788388 is a potent inhibitor of ALK5 and ALK4, thus indirectly influencing the signaling pathways of ACTR-IIA. | ||||||